Our data suggest that DON treatment affects the expression and possibly localization of multiple EGFR signaling proteins, redox enzymes as well as other proteins implicated in drug resistance of pancreatic cancer, leading to the inhibition of cancer cell proliferation and enhancement of chemosensitivity. Here, PROS1 is linked to familial pancreatic carcinoma.